Navigation Links
Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
Date:4/29/2008

TAMPA, Fla., April 29 /PRNewswire/ -- Quantum Immunologics, Inc. ("QI") announces the commencement of a Phase I/II clinical trial to assess the safety and efficacy of a novel anti-cancer vaccine/immunotherapy that will be used on patients with Stage IV advanced breast cancer. Patients accepted into the study have previously failed to respond to conventional therapy consisting of surgery, radiation and/or chemotherapy. QI has commissioned the study to be done by the original immunobiologists who developed the experimental immunotherapy. The clinical trial will be part of an FDA-authorized or effective investigator-sponsored Investigational New Drug application (IND).

This immuno-therapeutic experimental "vaccine" developed by scientists at the University of South Alabama (USA) is intended to activate the body's immune system against a cancer-specific protein to destroy the cancer cells. This immunizing protein, called the Oncofetal Antigen (OFA) or immature Laminin Receptor Protein (iLRP), is a universal cancer antigen or protein expressed in all human cancer types tested by the USA scientists thus far. Notably, this specific protein is not expressed on normal cells and tissues and thus is cancer-specific according to available assays.

Those patients with disseminated breast carcinomas and meeting the clinical trial entrance criteria will be treated under the above referenced IND at the Southern Cancer Center (SCC) in collaboration with clinicians at the Providence Cancer Center and other local oncology centers in and around Mobile, Alabama.

The investigators will collect from each patient's blood a white blood cell population called Dendritic Cells (DC). These cells are then exposed in vitro to replicated iLRP, cultured, and reintroduced into the patient via subdermal injection. The hope is that iLRP-sensitized DC will then recognize iLRP as a foreign protein or antigen on cancer cells and, when reintroduced into the body, will then, in turn, sensitize or introduce another group of immune cells known as T-killer lymphocytes, to the iLRP protein. The function of T-killer cells is to recognize foreign substances and initiate their destruction. Once these killer cells are activated against the iLRP protein on the cancer cells, it is further hoped that they will overwhelm and destroy the patients' breast cancer.

In a previous study recently undertaken in Austria, eleven advanced renal cell carcinoma patients who failed conventional therapy were treated with this type of immunotherapy. These patients developed a cytotoxic response secondary to activation of their T-killer cells against the iLRP protein using the same type of technique as in the present study. Five of the 11 patients are still alive with a median follow up of 46.7 months (range 33-54 months). The one-year survival rate was 90%; two-year survival rate - 54%; three-year survival rate - 45%. Notably though, the patients suffered no serious side effects from the therapy where most of the effects were flu-like symptoms secondary to the desired immune response. This study is designed to determine whether breast cancer patients will respond similarly and without toxicity.

This latest breast cancer study is the culmination of over 20 years of laboratory study and research of OFA with the support of the National Institutes of Health, including National Cancer Institute. The three senior immunobiologists, Drs. Joseph Coggin, Jim Rohrer and Adel Barsoum of the Department of Microbiology and Immunology at the University of South Alabama, will collaborate with the primary investigator, Dr. Paul Schwartzenberger, M.D., an SCC oncologist.

About Quantum Immunologics, Inc.

QI was formed for the sole purpose of developing, implementing and distributing new advanced levels of designer therapeutic treatments and diagnostic tools including all of the patents and intellectual properties acquired from USA by Venture Research Institute, Inc. (a southern California based private investment club) and its sister company, Investors Medical Fund, LLC. QI's mission is to foster the development and support for these and other technologies that are complementary to its current portfolio of patented intellectual properties that are focused on immune diseases and disorders. Mr. Chuck Broes, QI's CEO, states that they are currently assembling additional top scientists and professionals in the industry to carry out its mission. Mr. Broes further states that the philosophy of QI is to develop partnerships with other firms which are recognized leaders in their respective fields to implement the mission.

To learn more, visit http://www.quantumimmunologics.com.

Contacts:

For QI, Chuck Broes:

813-849-7885

2701 Rocky Point Dr., Ste. 325, Tampa, FL 33607

For USA/SAMSF, Dr. Paul Schwartzenberger, Chief Oncologist:

251-401-1975

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Quantum Immunologics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
2. Artists for a New South Africa Will be Shaking The Blues at Gala Benefit November 15, With Performances by Erykah Badu, Nikka Costa, Keb Mo, Taj Mahal Trio, The Roots, and Guest Stars at The Wiltern in Los Angeles
3. Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
4. Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. Globus Medical Raises $110 Million in Series E Financing Round
9. Quark Pharmaceuticals Appoints New Chief Medical Officer
10. Boston University Biomedical Engineers Find Chink in Bacterias Armor
11. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
Breaking Medicine News(10 mins):